Physician profile
Marina Kras
NPI 1891406427
$1,870.04
in general payments reported to CMS, 2019-2025
23 companies · $829 in 2025
The $829 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $894 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.41 | 2023-2025 | |
| Novo Nordisk INC | $145.61 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $143.98 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $115.83 | 2023-2025 | |
| Lilly USA, LLC | $100.58 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $95.65 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $90.61 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.61 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $73.53 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $63.76 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.83 | 2023-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $51.92 | 2025 | |
| Astellas Pharma US INC | $45.53 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $43.32 | 2023-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $42.08 | 2025 | Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.05 | 2024-2025 | Jardiance |
| Lundbeck LLC | $39.24 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $30.89 | 2024 | Voquezna |
| Mylan Specialty L.P. | $21.66 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $20.08 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $18.01 | 2025 | Yupelri |
| Amgen INC. | $17.05 | 2023 | Repatha, Otezla |
| Phadia US INC. | $14.81 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Kras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.